HEALTH● LOWAug 17 · Aug 17, 2026, 8:28 AM
Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositis
Seeking Alpha Tech
A company's drug, Vyvgart, has met key trial endpoints for autoimmune myositis, indicating progress in its development for this condition. This represents a significant step in medical research for autoimmune diseases.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH49m agoEditorial : At the CDC , damage control would be a big winrockymounttelegram.com · United StatesHEALTH1h agoIVF clinic’s embryo specimen mix-up linked to ‘intentional unlawful conduct’South China Morning PostHEALTH3h agoUS Study Tests Psilocybin To Fight Cancer Side EffectsChannels TVHEALTH4h agoAtiku decries Nigerians selling kidneys amid economic hardshipVanguard Nigeria